CBPD-409
CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 ; Blue: CRBN/cullin 4A Thalidomide (HY-14658) ; Black: Linker).
Product Specifications
CAS Number
3037549-86-0
UNSPSC
12352005
Target
Histone Acetyltransferase; PROTACs
Type
Reference compound
Related Pathways
Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cbpd-409.html
Purity
99.38
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1C2C(NC(CC2)=O)=O)C3=CC(N4CCN(C[C@@H]5CC[C@@H](N6C7=C(CN(C(C)=O)CC7)C(N8C9=C(CCC8)C=C(C(C(F)F)=C9)C%10=CN(C)N=C%10)=N6)CC5)CC4)=CC=C3C1=O
Molecular Formula
C46H52F2N10O5
Molecular Weight
862.97
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD31 / PECAM-1 (Endothelial Cell Marker) (PECAM1/3527), CF640R conjugate, 0.1mg/mL
P53 Tumor Suppressor Protein (rTP53/1739), CF640R conjugate, 0.1mg/mL
PAX8 (Renal Cell Marker) (PAX8/1492), Biotin conjugate, 0.1mg/mL
